HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?

AbstractBACKGROUND:
Indoleamine 2,3-dioxygenase (IDO) is an emerging immunomodulating factor in cancer. IDO expression in tumour-negative sentinel lymph nodes (SLNs) of patients with melanoma has a negative prognostic value.
OBJECTIVES:
To analyse the expression pattern of IDO and associated immunological changes in corresponding primary melanomas (PMs), SLNs and metastases.
METHODS:
In 120 patients with melanoma, PMs with corresponding SLNs (n = 85) and metastases (n = 18) were analysed by immunohistochemical staining for IDO and FoxP3. Tumour-infiltrating lymphocytes (TILs) were scored. IDO expression in stimulated peripheral blood mononuclear cells (PBMCs) was analysed in 27 patients.
RESULTS:
IDO expression in the sentinel node strongly correlated with endothelial IDO expression in the peritumoral stroma of the corresponding primary (P < 0·001) and metastatic melanoma (P < 0·05). Sentinel IDO positivity was inversely correlated with CD8+ lymphocytes (P = 0·01) and TILs (P = 0·05) in PM. Both IDO expression in the sentinel (P < 0·01) and the PM (P = 0·04) had a negative prognostic effect on overall survival, independent of Breslow thickness, sex, age, ulceration and sentinel invasion. IDO expression by PBMCs after stimulation with cytotoxic T-lymphocyte antigen 4 was not correlated with sentinel IDO expression but tended to correlate with disease stage (P = 0·04).
CONCLUSIONS:
Endothelial IDO expression is highly consistent in primary, sentinel and metastatic tissues of patients with melanoma, indicating that immune suppression in melanoma is determined very early in the disease course. This supports that IDO expression in melanoma is a marker of antitumour immune response with an independent prognostic value.
AuthorsI Chevolet, R Speeckaert, M Haspeslagh, B Neyns, V Krüse, M Schreuer, M Van Gele, N Van Geel, L Brochez
JournalThe British journal of dermatology (Br J Dermatol) Vol. 171 Issue 5 Pg. 987-95 (Nov 2014) ISSN: 1365-2133 [Electronic] England
PMID24814041 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2014 British Association of Dermatologists.
Chemical References
  • Biomarkers, Tumor
  • Indoleamine-Pyrrole 2,3,-Dioxygenase
Topics
  • Adult
  • Biomarkers, Tumor (metabolism)
  • CD8-Positive T-Lymphocytes (immunology)
  • Endothelial Cells (immunology)
  • Female
  • Humans
  • Immune Tolerance (immunology)
  • Indoleamine-Pyrrole 2,3,-Dioxygenase (metabolism)
  • Lymph Nodes (immunology, metabolism)
  • Lymphatic Metastasis
  • Lymphocytes, Tumor-Infiltrating (immunology)
  • Male
  • Melanoma (immunology, metabolism)
  • Middle Aged
  • Prognosis
  • Skin Neoplasms (immunology, metabolism)
  • Tumor Escape (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: